{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:18Z","timestamp":1707524958945},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,24]]},"DOI":"10.7759\/cureus.35436","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T07:40:46Z","timestamp":1677310846000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Metastatic Small Cell Carcinoma of Lung in a Follow-Up Patient of Chronic Myeloid Leukemia on Imatinib Treatment"],"prefix":"10.7759","author":[{"given":"Anurag","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nida","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailendra P","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley JF","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015, 385:1447-59. 10.1016\/S0140-6736(13)62120-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV","volume":"30","author":"Miranda MB","year":"2016","unstructured":"Miranda MB, Lauseker M, Kraus MP, et al.. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016, 30:1255-62. 10.1038\/leu.2016.20","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180390","article-title":"Review of risk factors of secondary cancers among cancer survivors","volume":"92","author":"Demoor-Goldschmidt C","year":"2019","unstructured":"Demoor-Goldschmidt C, de Vathaire F. Review of risk factors of secondary cancers among cancer survivors. Br J Radiol. 2019, 92:20180390. 10.1259\/bjr.20180390","journal-title":"Br J Radiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.09.013","article-title":"Second cancer after radiotherapy, 1981-2007","volume":"105","author":"Bartkowiak D","year":"2012","unstructured":"Bartkowiak D, Humble N, Suhr P, et al.. Second cancer after radiotherapy, 1981-2007. Radiother Oncol. 2012, 105:122-6. 10.1016\/j.radonc.2011.09.013","journal-title":"Radiother Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/387450a0","article-title":"DNA repair. A sense-abl response?","volume":"387","author":"Brown L","year":"1997","unstructured":"Brown L, McCarthy N. DNA repair. A sense-abl response?. Nature. 1997, 387:450-1. 10.1038\/387450a0","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna S","year":"2009","unstructured":"Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009, 8:547-66. 10.1038\/nrd2907","journal-title":"Nat Rev Drug Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0069","article-title":"Effects of imatinib on normal hematopoiesis and immune activation","volume":"23","author":"Appel S","year":"2005","unstructured":"Appel S, Balabanov S, Br\u00fcmmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005, 23:1082-8. 10.1634\/stemcells.2005-0069","journal-title":"Stem Cells"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius A","year":"2015","unstructured":"Fabarius A, Kalmanti L, Dietz CT, et al.. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015, 94:2015-24. 10.1007\/s00277-015-2494-9","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.666545","article-title":"Secondary malignancy after imatinib therapy: eight cases and review of the literature","volume":"53","author":"Duman BB","year":"2012","unstructured":"Duman BB, Paydas S, Disel U, Besen A, Gurkan E. Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leuk Lymphoma. 2012, 53:1706-8. 10.3109\/10428194.2012.666545","journal-title":"Leuk Lymphoma"},{"key":"ref10","article-title":"New malignancies among cancer survivors: SEER cancer registries, 1973-2000. US Department of Health and Human Services, National Institutes of Health","year":"2006","unstructured":"New Malignancies Among Cancer Survivors. SEER Cancer Registries, 1973-2000. Curtis RE, Freedman DM, Ron E, et al. (ed): National Cancer Institute, Bethesda, MD; 2006. https:\/\/seer.cancer.gov\/archive\/publications\/mpmono\/MPMonograph_complete.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq262","article-title":"Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study","volume":"172","author":"Rebora P","year":"2010","unstructured":"Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol. 2010, 172:1028-33. 10.1093\/aje\/kwq262","journal-title":"Am J Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1159-7","article-title":"Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors","volume":"35","author":"Nakazato T","year":"2018","unstructured":"Nakazato T, Iriyama N, Tokuhira M, et al.. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018, 35:99. 10.1007\/s12032-018-1159-7","journal-title":"Med Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia","volume":"19","author":"Roy L","year":"2005","unstructured":"Roy L, Guilhot J, Martineau G, Larch\u00e9e R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia. 2005, 19:1689-92. 10.1038\/sj.leu.2403874","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini C","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, et al.. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011, 103:553-61. 10.1093\/jnci\/djr060","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin CM","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021, 7:3. 10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.034","article-title":"Current diagnosis and management of small-cell lung cancer","volume":"94","author":"Wang S","year":"2019","unstructured":"Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019, 94:1599-622. 10.1016\/j.mayocp.2019.01.034","journal-title":"Mayo Clin Proc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0079-2021","article-title":"Recent developments in the treatment of small cell lung cancer","volume":"30","author":"Hiddinga BI","year":"2021","unstructured":"Hiddinga BI, Raskin J, Janssens A, Pauwels P, Van Meerbeeck JP. Recent developments in the treatment of small cell lung cancer. Eur Respir Rev. 2021, 30:10.1183\/16000617.0079-2021","journal-title":"Eur Respir Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/139929-a-rare-case-of-metastatic-small-cell-carcinoma-of-lung-in-a-follow-up-patient-of-chronic-myeloid-leukemia-on-imatinib-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:12Z","timestamp":1707508812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/139929-a-rare-case-of-metastatic-small-cell-carcinoma-of-lung-in-a-follow-up-patient-of-chronic-myeloid-leukemia-on-imatinib-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.35436","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}